A5103058084- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Nutrition, Genetics, and Disease
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Genomic variations and chromosomal abnormalities
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Genetics, Bioinformatics, and Biomedical Research
- Lung Cancer Diagnosis and Treatment
- DNA Repair Mechanisms
- Melanoma and MAPK Pathways
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Ferroptosis and cancer prognosis
- Molecular Biology Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Genetic Associations and Epidemiology
- Glioma Diagnosis and Treatment
- CRISPR and Genetic Engineering
Athens Medical Center
2016-2024
Athens Naval & Veterans Hospital
2019
Metropolitan Hospital
2019
Euromedica
2019
St. Luke's Hospital
2019
Institutul Oncologic Bucuresti
2018
Spitalul Clinic Județean de Urgență Cluj-Napoca
2018
Creative Research Enterprises (United States)
2016
Non‑small cell lung cancer (NSCLC) is the most common type of and a tumor with broad spectrum targeted therapies already available or in clinical trials. Thus, molecular characterization using next generation sequencing (NGS) technology, has become key tool for facilitating treatment decisions management NSCLC patients. The performance custom 23 gene multiplex amplification hot spot panel, based on Ion AmpliSeq™ was evaluated analysis DNA extracted from formalin-fixed paraffin-embedded...
Analysis of circulating tumor nucleic acids in plasma Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form "liquid biopsy" provides real-time information on molecular profile without an invasive tissue biopsy.Liquid biopsy analysis was requested by referral physician 121 NSCLC at diagnosis performed using a sensitive Next Generation Sequencing assay. Additionally, comparative relapse following EGFR Tyrosine Kinase Inhibitor (TKIs) treatment 50 both cobas NGS...
Background: Hereditary cancer predisposition syndromes are responsible for approximately 5–10% of all diagnosed cases. In order to identify individuals at risk in a cost-efficient manner, family members carrying pathogenic alterations tested only the specific variant that was identified their carrier relative. The purpose this study investigate clinical use and implementation cascade testing (CFT) families breast patients with pathogenic/likely variants (PVs/LPVs) cancer-related genes....
It has been reported that certain patients with non-small-cell lung cancer (NSCLC) harbor activating somatic mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) gene may be effectively treated using targeted therapy. The use EGFR inhibitors in patient therapy demonstrated to improve response and survival rates; therefore, it was suggested clinical screening for should performed all patients. Numerous clinicopathological factors have associated Kirsten-rat...
<h3>Abstract</h3> Background/Aim: Germline copy number variation (CNV) is a type of genetic variant that predisposes significantly to inherited cancers. Today, next-generation sequencing (NGS) technologies have contributed multi gene panel analysis in clinical practice. Materials and Methods: A total 2,163 patients were screened for cancer susceptibility, using solution-based capture method. 52 genes was used targeted NGS. The capture-based approach enables computational CNVs from NGS data....
Abstract Background Tumor molecular profile analysis by Next Generation Sequencing technology is currently widely applied in clinical practice and has enabled the detection of predictive biomarkers response to targeted treatment. In parallel with therapies, immunotherapies are also evolving, revolutionizing cancer therapy, Programmed Death-ligand 1 (PD-L1), Microsatellite instability (MSI), Mutational Burden (TMB) being employed most commonly. Methods present study, tumor was performed using...
Pancreatic cancer stands out as one of the most lethal forms malignancies, representing 2% all cases and contributing to 5% cancer-related fatalities. Therefore, early detection pancreatic is crucial for enhancing treatment outcomes. Various hereditary syndromes have been linked an elevated risk developing cancer, suggesting potential benefits from surveillance strategies individuals at risk. Presently, precision medicine employs PARP inhibitor therapy patients carrying germline variants in...
Background/Aim: The use of multi-gene panels for germline testing in breast cancer enables the estimation risk and guides risk-reducing management options. aim this study was to present data that demonstrate different levels actionability used genetic patients their family members. Materials Methods: We performed an analysis our clinical database identify undergoing testing. reviewed positive results respect management, cascade testing, secondary findings information treatment...
Breast cancer remains the most prevalent type of among women worldwide, and it primary cause cancer-related deaths in this demographic. Neuroendocrine breast (NBC), an uncommon subtype comprising less than 1% cases, typically occurs older displays as a slow-growing, low-grade condition. NBC exhibits distinct histological patterns immunohistochemical markers. Given limited data on NBC, assays are required that will provide information molecular profiling assist clinical decision making. The...
Abstract AIM Endocrine therapy (ET) represents the first line treatment for patients with ER+, HER2- breast cancer, however disease progression is observed in many cases. PIK3CA and ESR1 are most encountered mutated genes that have been associated targeted molecular treatment, as well resistance to Therapy. Liquid biopsy a non-invasive procedure, can provide “real-time” monitoring of response treatment. The aim this study determine mutation rate selected cohort 200 Greek cancer patients,...
Breast cancer (BC) is the most prominent tumor type among women, accounting for 32% of newly diagnosed cases. BC risk factors include inherited germline pathogenic gene variants and family history disease. However, etiology disease remains occult in Therefore, absence high-risk factors, a polygenic basis has been suggested to contribute susceptibility. This information utilized calculate Polygenic Risk Score (PRS) which indicative risk. study aimed evaluate retrospectively clinical...
e16276 Background: Pancreatic cancer is one of the most fatal malignancies. It accounts for 2% all cancers and 5% cancer-related deaths. Hence, it essential to identify pancreatic at an earlier stage improve outcomes. A variety hereditary syndromes have been associated with increased risk developing cancer, these individuals may benefit from surveillance plans. PARP inhibitor therapy currently being applied as precision medicine patients harboring germline variant in Homologous recombination...
e23193 Background: Non-small cell lung cancer (NSCLC) is the most common type of and a tumor with broad spectrum targeted therapies already available or in clinical trials. Thus, molecular characterization using Next Generation Sequencing (NGS) technology, has become key tool for NSCLC patients’ treatment decision management. Methods: The performance custom 23 gene multiplex amplification hot spot panel, based on Ion AmpliSeq Technology, was evaluated analysis DNA extracted from FFPE...
e12534 Background: The purpose of this analysis is to evaluate how many patients previously treated according OncotypeDX Recurrence Score (RS) could have been spared Chemotherapy if the TAILORx RS data had taken into account in clinical treatment decisions. Methods: A series 182 patients, 34-74 years age with early breast cancer, our Breast Unit during last 10 years, for whom decisions were based on RS. Scores all these obtained and actual that made pre-TAILORx cut-offs 18 31 recorded. These...
e12536 Background: Approximately 5-10% of breast cancer cases are hereditary. Germline mutations in the BRCA1 and BRCA2genes responsible for 80% inherited cases. Carriers such usually members families with at least 1-2 diagnosed before age 40 years. Pathogenic throughout coding region two genes have been identified. Founder identified various populations. AIM: To date there limited data on contribution Turkish cancer. We aimed to identify high risk patients this population, as judged by...
e22178 Background: NSCLC patients harboring activating somatic mutations within the tyrosine kinase (TK) domain of epidermal growth factor receptor (EGFR) significantly benefit from EGFR targeted therapy; therefore screening for has entered routine clinical practice. Several clinico-pathological factors correlate with and KRAS including gender, smoking history, histology. The frequency is also ethnicity-dependent, wherein incidence in Caucasians ~ 15%. However, limited data available on...
e15169 Background: Several tumor types have been efficiently treated with PARP inhibitors, a class of proteins involved in DNA repair pathway, which are approved for the treatment ovarian, breast, prostate, and pancreatic cancer. The BRCA1/2 genes essential homologous recombination, tumors carry this type mutations appear to defective recombination pathway as result loss second non mutated allele tumor. However, both epigenetic changes many other HR including Fanconi anemia ΑRID1A, ATM,...
Abstract AIM: Most patients tested by a 44-gene panel for hereditary cancer (HerediGene), even though they had strong family history, have negative result or finding in low-risk gene. This creates question about the risk these individuals to develop breast cancer. The Polygenic Risk Score is tool used identify and calculate lifetime of developing thus we are investigating whether it can be our cohort this risk. PATIENTS AND METHODS: Among 111 analyzed with panel, were able produce 105 them....
Abstract AIM: The majority of invasive lobular carcinomas (ILC) the breast are luminal A tumors good prognosis, having a low or intermediate OncotypeDX Recurrence Score (RS). They usually treated with hormonal therapy only and some have doubted relevance RS for patients ILC. However, in number ILC cases high can be found, indicating chemotherapy benefit. aim present analysis was to explore our database analyzed OncotypeDX, percentage &gt;25 test hypothesis if Progesterone Receptor (PgR)...
Abstract INTRODUCTION Hereditary breast cancer is estimated to account for approximately 10% of all cases. In addition, an 15-20% those affected by have a positive family history. Despite the fact that BRCA1 and BRCA2 are two most significant genes in hereditary predisposition, twenty years analysis has highlighted fact, mutations these highly penetrant genes, only present 20% high risk families. Other which associated with cancer, were identified because strong association familial...
Abstract BACKGOUND: Hereditary cancer predisposition syndromes are believed to be responsible for approximately 5-10% of all diagnosed cases. In the past, single genes analysis certain high risk was used determination genetic cause heritability in families. The selection mainly based on family history individuals analyzed and included only highly associated (e.g. BRCA1 BRCA2 families with breast history. Nowadays though, application Next Generation Sequencing (NGS) technology has facilitated...